XML 76 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
Financial Information By Quarter (Unaudited) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Quarterly Financial Information [Abstract]                      
Research and development $ 1,412,000 $ 1,390,000 $ 4,265,000 $ 5,202,000 $ 7,159,000 $ 4,658,000 $ 1,901,000 $ 1,270,000 $ 12,268,960 $ 14,987,628 $ 8,175,878
Selling, general and administrative expense 3,281,000 3,094,000 3,058,000 2,870,000 4,464,000 2,855,000 3,739,000 2,656,000 12,303,050 13,713,635 10,582,068
Research and development expense 2,781,000 2,471,000 5,068,000 6,360,000 8,158,000 6,069,000 2,948,000 2,536,000 16,679,712 19,710,673 13,130,529
Patent expenses 221,000 251,000 197,000 241,000 219,000 230,000 240,000 220,000 909,946 909,376 1,009,053
Lease termination 0 1,225,000 0 0         1,225,421 0 0
Interest on PharmAthene liability         927,000 3,566,000 4,259,000 2,917,000 0 11,668,900 0
Operating loss (4,871,000) (5,651,000) (4,059,000) (4,269,000) (6,609,000) (8,062,000) (9,285,000) (7,059,000) (18,849,169) (31,014,956) (30,953,266)
Net income (loss) $ (10,303,000) $ (9,816,000) $ (7,501,000) $ (8,615,000) $ (10,439,000) $ (9,244,000) $ (9,566,000) $ (10,449,000) $ (36,235,484) $ (39,697,960) $ (39,451,324)
Earnings (loss) per share: basic and diluted (usd per share) $ (0.13) $ (0.12) $ (0.10) $ (0.11) $ (0.15) $ (0.17) $ (0.18) $ (0.19) $ (0.46) $ (0.69) $ (0.73)